EP1024696A4 - Kombinationstherapie zur reduzierung der mit kardio- und zerebrovaskulären erkrankungen verbundenen risiken - Google Patents

Kombinationstherapie zur reduzierung der mit kardio- und zerebrovaskulären erkrankungen verbundenen risiken

Info

Publication number
EP1024696A4
EP1024696A4 EP98957328A EP98957328A EP1024696A4 EP 1024696 A4 EP1024696 A4 EP 1024696A4 EP 98957328 A EP98957328 A EP 98957328A EP 98957328 A EP98957328 A EP 98957328A EP 1024696 A4 EP1024696 A4 EP 1024696A4
Authority
EP
European Patent Office
Prior art keywords
cardiovascular
reduce
cerebrovascular diseases
risks related
association therapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP98957328A
Other languages
English (en)
French (fr)
Other versions
EP1024696A1 (de
Inventor
Melvin Winokur
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9806688.9A external-priority patent/GB9806688D0/en
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of EP1024696A1 publication Critical patent/EP1024696A1/de
Publication of EP1024696A4 publication Critical patent/EP1024696A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Furan Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
EP98957328A 1997-10-22 1998-10-16 Kombinationstherapie zur reduzierung der mit kardio- und zerebrovaskulären erkrankungen verbundenen risiken Withdrawn EP1024696A4 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US6269197P 1997-10-22 1997-10-22
US62691P 1997-10-22
GB9806688 1998-03-27
GBGB9806688.9A GB9806688D0 (en) 1998-03-27 1998-03-27 Combination therapy for reducing the risks associated with cardio-and cerebrovascular diease
PCT/US1998/021901 WO1999020110A1 (en) 1997-10-22 1998-10-16 Combination therapy for reducing the risks associated with cardio- and cerebrovascular disease

Publications (2)

Publication Number Publication Date
EP1024696A1 EP1024696A1 (de) 2000-08-09
EP1024696A4 true EP1024696A4 (de) 2004-07-14

Family

ID=26313383

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98957328A Withdrawn EP1024696A4 (de) 1997-10-22 1998-10-16 Kombinationstherapie zur reduzierung der mit kardio- und zerebrovaskulären erkrankungen verbundenen risiken

Country Status (5)

Country Link
EP (1) EP1024696A4 (de)
JP (1) JP2001520174A (de)
AU (1) AU753657B2 (de)
CA (1) CA2306646A1 (de)
WO (1) WO1999020110A1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6184248B1 (en) * 1996-09-05 2001-02-06 Robert K. K. Lee Compositions and methods for treatment of neurological disorders and neurodegenerative diseases
EP1197228A4 (de) * 1999-07-02 2004-03-10 Hisamitsu Pharmaceutical Co Arzneimittel für die behandlung von kolorektalem krebs
ES2328446T5 (es) 2000-02-04 2014-02-27 Children's Hospital Research Foundation Uso de lipasa ácida lisosomal para tratar la aterosclerosis y enfermedades asociadas
GB2361185A (en) * 2000-04-10 2001-10-17 Nicholas J Wald Pharmaceutical formulation for the prevention of cardiovascular disease
NZ524252A (en) 2000-07-20 2004-03-26 Lauras As Cox-2 inhibitors for treating HIV and AIDS
US6534540B2 (en) 2000-10-06 2003-03-18 George Kindness Combination and method of treatment of cancer utilizing a COX-2 inhibitor and a 3-hydroxy-3-methylglutaryl-coenzyme-a (HMG-CoA) reductase inhibitor
WO2002028270A2 (en) * 2000-10-06 2002-04-11 Probiochem, Llc The treatment of cancer utilizing a cox-2 inhibitor and a hmg-coa reductase inhibitor
WO2002094021A1 (en) * 2000-10-06 2002-11-28 Probiochem, Llc A combination and method of treatment of cancer utilizing a cox-2 inhibitor and an hmg-coa inhibitor and cystine to enhance glutathione
DE60122939T2 (de) 2000-12-21 2007-01-11 Nitromed, Inc., Bedford Substituierte arylverbindungen als neue, cyclooxygenase-2-selektive inhibitoren, zusammensetzungen und verwendungsverfahren
CN100341509C (zh) * 2002-07-11 2007-10-10 三共株式会社 用于改善血液中脂质或降低血液中高半胱氨酸的药物组合物
JP4611622B2 (ja) * 2002-07-11 2011-01-12 第一三共株式会社 血中脂質改善又は血中ホモシステイン低下のための医薬組成物
KR101310037B1 (ko) 2005-05-31 2013-09-24 밀란 인크. 네비볼롤을 함유하는 조성물
US20070037797A1 (en) * 2005-08-15 2007-02-15 Hellstrom Harold R Method of reducing the risk of adverse cardiovascular (CV) events associated with the administration of pharmaceutical agents which favor CV events
SG166829A1 (en) * 2005-11-08 2010-12-29 Ranbaxy Lab Ltd Process for (3r, 5r)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4- [(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3, 5-dihydroxy-heptanoic acid hemi calcium salt
US8404275B2 (en) * 2007-07-01 2013-03-26 Vitalis Llc Combination tablet with chewable outer layer
US9226891B2 (en) 2011-10-28 2016-01-05 Vitalis Llc Anti-flush compositions

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0671170A1 (de) * 1994-03-11 1995-09-13 Bristol-Myers Squibb Company Verwendung von Pravastatin zur Verlangsamung des Fortschreitens der Atherosklerose koronarer Arterien
WO1997032575A1 (en) * 1996-03-05 1997-09-12 Children's Hospital Medical Center Mercapto derivatives as inhibitors of cyclooxygenases

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6274896A (en) * 1995-06-06 1996-12-24 Procyte Corporation Stable copper(i) complexes as active therapeutic substances

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0671170A1 (de) * 1994-03-11 1995-09-13 Bristol-Myers Squibb Company Verwendung von Pravastatin zur Verlangsamung des Fortschreitens der Atherosklerose koronarer Arterien
WO1997032575A1 (en) * 1996-03-05 1997-09-12 Children's Hospital Medical Center Mercapto derivatives as inhibitors of cyclooxygenases

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO9920110A1 *

Also Published As

Publication number Publication date
EP1024696A1 (de) 2000-08-09
AU753657B2 (en) 2002-10-24
CA2306646A1 (en) 1999-04-29
AU1361299A (en) 1999-05-10
WO1999020110A1 (en) 1999-04-29
JP2001520174A (ja) 2001-10-30

Similar Documents

Publication Publication Date Title
IL132318A0 (en) Substituted imidazoles useful in the treatment of inflammatory diseases
DE69733943D1 (de) Verbesserung des sehens durch photodynamische therapie des auges
FR2767697B1 (fr) Composition dermatologique permettant d'eviter l'apparition de symptomes d'hypersensibilite et d'intolerance cutanee
DE69513919D1 (de) Sprachanalyse
DK0732379T3 (da) Pigmentholdigt kompositmateriale
DE59304927D1 (de) Diacrylate und Dimethacrylate
DK0727466T3 (da) Pigmentholdigt kompositmateriale
HUP9900147A3 (en) Therapeutic agents and autoimmune diseases
IL133088A0 (en) Novel triptolide derivatives useful in the treatment of autoimmune diseases
EP0921719A4 (de) Gene, welche die krankheitsresistenz in pflanzen erhöhen
ZA984177B (en) Novel triptolide derivatives useful in the treatment of autoimmune diseases
EP0934488A4 (de) Integrierter strahlformer und entsprechendes herstellungsverfahren
PL346796A1 (en) Methods of downmodulating the immune response to therapeutic proteins
KR970000470U (ko) 하체 단련 완력기
SK904U (sk) Logopedická sonda "L"
IL114045A0 (en) Body refreshener for the swimming pool and beach
FR2744637B1 (fr) L'exerciseur des cuisses et des fessiers
GB0120368D0 (en) Assays therapeutic methods and means
GB9514770D0 (en) Improvements in or relating to therapeutic antibodies
KR970027160U (ko) 종합신체단련기구
GB9414254D0 (en) Improvements in or relating to therapeutic antibodies
TW319975U (en) The structure of air-permeable and healthy shoes
KR970018940U (ko) 실내용 조립식 파라솔
KR970007940U (ko) 조립식 받침대
SI0983275T1 (en) Novel triptolide derivatives useful in the treatment of autoimmune diseases

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20000522

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU NL PT SE

AX Request for extension of the european patent

Free format text: AL PAYMENT 20000522;LT PAYMENT 20000522;LV PAYMENT 20000522;MK PAYMENT 20000522;RO PAYMENT 20000522;SI PAYMENT 20000522

A4 Supplementary search report drawn up and despatched

Effective date: 20040601

RIC1 Information provided on ipc code assigned before grant

Ipc: 7A 01N 43/16 A

17Q First examination report despatched

Effective date: 20041110

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20060210